EUVIMEDEUVIMED entdecken
Open Access

A Switch Protein Adapter for Anti‐LILRB4 CAR‐T Cells

Ryan Huang, Heyu Chen, Jingjing Xie, Qi Lou, Lingxiao Tan, Ningyan Zhang, Zhiqiang An, Samuel John, Cheng Cheng Zhang iD

European Journal of Immunology · 2025

DOI: 10.1002/eji.202451172 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Immunology, 2025. Verfasst von Ryan Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Receptors, Immunologic, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Cancer Institute, National Institutes of Health, NIAID NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor‐T cell (CAR‐T) immunotherapy has shown remarkable results for the treatment of certain hematologic malignancies. A redirection strategy that utilizes clinically relevant CAR‐T cells in combination with adapter proteins may be an effective strategy to target other hematologic and solid cancers. We established a fusion antibody‐based strategy with flexibility to target multiple tumor types in combination with a novel anti‐leukocyte immunoglobulin‐like receptor‐B 4 (LILRB4) CAR‐T cell. Specifically, we engineered switch protein (SwP) adapters containing the LILRB4 extracellular domain fused to either an anti‐CD19 or anti‐CD20 single‐chain variable fragment (scFv). These SwPs were sufficient to stimulate anti‐LILRB4 CAR‐T cells against SwP‐tagged LILRB4 ‐ CD19 + and LILRB4 ‐ CD20 + cancers in vitro and in vivo. This strategy may allow CAR‐T cells to be redirected against a variety of tumor antigens and cancer types and become a valuable approach to expand the impact of cellular immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, ImmunologicImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesNeoplasmsMembrane GlycoproteinsHumansAnimalsAntigens, CD19MiceSingle-Chain AntibodiesCell Line, TumorAntigens, CD20

Stichwörter der Autor:innen

cancerchimeric antigen receptor‐T (CAR‐T)inhibitory receptorleukocyte immunoglobulin‐like receptor‐B 4 (LILRB4)switch proteintumor microenvironmentuniversal chimeric antigen receptor‐T (CAR‐T)

Substanzen

Receptors, ImmunologicReceptors, Chimeric AntigenAntigens, CD19LILRB4 protein, humanSingle-Chain AntibodiesAntigens, CD20Membrane Glycoproteins

Autor:innen und Institutionen

  • Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas, USA.
  • Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

ORCID-Profile: Cheng Cheng Zhang

Förderung

  • National Cancer Institute, National Institutes of Health
  • NIAID NIH HHS
  • NCI NIH HHS
  • Immune-Onc Therapeutics Inc. Sponsored Research Grant
  • Leukemia and Lymphoma Society
  • U.S. Department of Defense

Zitieren

APA

Huang, R., Chen, H., Xie, J., Lou, Q., Tan, L., Zhang, N., An, Z., John, S., & Zhang, C. C. (2025). A Switch Protein Adapter for Anti‐LILRB4 CAR‐T Cells. European Journal of Immunology. https://doi.org/10.1002/eji.202451172

Vancouver

Huang R, Chen H, Xie J, Lou Q, Tan L, Zhang N, et al. A Switch Protein Adapter for Anti‐LILRB4 CAR‐T Cells. European Journal of Immunology. 2025. doi:10.1002/eji.202451172

BibTeX
@article{Huang2025,
  author = {Huang, Ryan and Chen, Heyu and Xie, Jingjing and Lou, Qi and Tan, Lingxiao and Zhang, Ningyan and An, Zhiqiang and John, Samuel and Zhang, Cheng Cheng},
  title = {A Switch Protein Adapter for Anti‐LILRB4 CAR‐T Cells},
  journal = {European Journal of Immunology},
  year = {2025},
  doi = {10.1002/eji.202451172}
}
Kostenlos starten →